DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Desjardins Global Asset Management Inc.

Desjardins Global Asset Management Inc. lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 15.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,074 shares of the medical device company’s stock after acquiring an additional 282 shares during the period. Desjardins Global Asset Management Inc.’s holdings in DexCom were worth $257,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in DXCM. Norges Bank acquired a new stake in shares of DexCom during the fourth quarter valued at $421,378,000. Winslow Capital Management LLC acquired a new stake in shares of DexCom during the third quarter valued at $173,120,000. Vaughan Nelson Investment Management L.P. boosted its stake in shares of DexCom by 16,943.0% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 1,459,730 shares of the medical device company’s stock valued at $136,193,000 after acquiring an additional 1,451,165 shares during the last quarter. 1832 Asset Management L.P. acquired a new stake in shares of DexCom during the fourth quarter valued at $151,538,000. Finally, Clearbridge Investments LLC boosted its stake in shares of DexCom by 304.3% during the first quarter. Clearbridge Investments LLC now owns 1,318,079 shares of the medical device company’s stock valued at $674,329,000 after acquiring an additional 992,049 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $134.30 on Friday. The firm has a market capitalization of $51.77 billion, a P/E ratio of 102.52, a P/E/G ratio of 2.35 and a beta of 1.20. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. The business’s 50-day simple moving average is $129.35 and its 200-day simple moving average is $116.41.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.07. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company’s revenue was up 26.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.34 EPS. Equities analysts predict that DexCom, Inc. will post 1.76 EPS for the current year.

Insider Activity at DexCom

In related news, CFO Jereme M. Sylvain sold 3,363 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at approximately $8,304,405.66. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CFO Jereme M. Sylvain sold 3,363 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at approximately $8,304,405.66. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Jereme M. Sylvain sold 11,661 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total value of $1,567,355.01. Following the sale, the chief financial officer now owns 85,534 shares in the company, valued at $11,496,624.94. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have issued reports on the company. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada assumed coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target on the stock. UBS Group raised their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Raymond James raised their price target on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 23rd. Finally, Citigroup raised their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $141.40.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.